

1
2 UNITED STATES DISTRICT COURT
3 SOUTHERN DISTRICT OF CALIFORNIA

4 IN RE: INCRETIN-BASED
5 THERAPIES PRODUCTS
6 LIABILITY LITIGATION

7 *This Document Relates to All Cases*

Case No. 13-md-2452-AJB-MDD

JOINT MOTION FOR EXTENSION OF
TIME TO FILE PROPOSED
SCHEDULING ORDER

Judge: Hon. Anthony J. Battaglia
Magistrate: Hon. Mitchell D. Dembin

8
9
10 Pursuant to the Court's November 25, 2013 Order Following Second
11 Status Conference and Staying Submission of Plaintiff Fact Sheets (Doc.
12 No. 200) (the "Order"), the undersigned counsel for the Plaintiffs, together
13 with undersigned counsel for Defendants Amylin Pharmaceuticals, LLC
14 ("Amylin"), Eli Lilly and Company ("Lilly"), Merck Sharp & Dohme Corp.,
15 and Novo Nordisk Inc. (collectively, the "Parties") hereby jointly move the
16 Court, in accord with Rule 7.2 of the Local Rules for the United States
17 District Court for the Southern District of California, to extend the time for
18 compliance with Paragraph 2 of the Order.

19 Paragraph 2 of the Order requires the parties to "submit a Joint
20 Motion for Entry of a Case Management Scheduling Order detailing the
21 utilization of Bellwether trials in this action, and proposed deadlines for
22 filing dispositive motions, *Daubert* motions, and any other related motions.
23 The Joint Motion must be filed no later than **January 10, 2014**. To the
24 extent the parties disagree, the Joint Motion must set forth the areas in which
25 the parties agree and the parties' respective disagreements. The parties will
26 separately file a proposed plan for the utilization of Bellwether trials in this
27 action. The proposed plan will take into account the state court cases filed in
28 the JCCP and must be submitted no later than **January 10, 2014.**"

1 The Parties have been involved in discussions related to the entry of a
2 Case Management Scheduling Order as contemplated by Paragraph 2 of the
3 Order; however, there are issues that remain to be resolved. The Parties
4 believe that an additional 30 days will allow the Parties to continue their
5 discussions so as to minimize or eliminate issues to be presented to this
6 Court for resolution.

7 Accordingly, Plaintiffs and Defendants hereby move the Court to
8 grant the Parties an extension of time within which to comply with
9 Paragraph 2, so that the filings required by Paragraph 2 shall be due to the
10 Court on or before February 10, 2014.

11 Respectfully submitted:

12 Dated: January 8, 2014

RYAN L. THOMPSON
WATTS GUERRA LLP

13 By: /s/ Ryan L. Thompson

14 Ryan L. Thompson
15 Plaintiffs' Counsel

16 Dated: January 8, 2014

HUNTER J. SHKOLNIK
NAPOLI BERN RIPKA SHKOLNIK

17 By: /s/ Hunter J. Shkolnik

18 Hunter J. Shkolnik
19 Plaintiffs' Counsel

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Dated: January 8, 2014

TOR A. HOERMAN
JACOB W. PLATTENBERGER
TORHOERMAN LAW LLC

By: /s/ Tor A. Hoerman
Tor A. Hoerman
Plaintiffs' Counsel

Dated: January 8, 2014

NINA M. GUSSACK
KENNETH J. KING
PEPPER HAMILTON LLP

By: /s/ Kenneth J. King
Kenneth J. King
Attorneys for Defendant
Eli Lilly and Company, a
corporation

Dated: January 8, 2014

RICHARD B. GOETZ
AMY J. LAURENDEAU
O'MELVENY & MYERS LLP

By: /s/ Amy J. Laurendeau
Amy J. Laurendeau
Attorneys for Defendant
Amylin Pharmaceuticals, LLC

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Dated: January 8, 2014

DOUGLAS MARVIN
EVA ESBER
PAUL BOEHM
WILLIAMS & CONNOLLY LLP

By: /s/ Paul Boehm
Paul Boehm
Attorneys for Defendant
Merck Sharp & Dohme Corp.

Dated: January 8, 2014

LOREN BROWN
HEIDI LEVINE
RAYMOND WILLIAMS
DLA PIPER

By: /s/ Heidi Levine
Heidi Levine
Attorneys for Defendant
Novo Nordisk Inc.